Study: Teva's Copaxone the Better Treatment Option for MS

KEYWORDS Industry / Markets
A A

Teva Pharmaceutical’s multiple sclerosis (MS) agent Copaxone is a better treatment for patients with relapsing-remitting MS compared with interferon beta drug products, a recent study found.

To View This Article:

Login

Subscribe To Drug Industry Daily